Aggressive Non-Hodgkin Lymphoma — Trials

Aggressive Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

648 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 182
Recruiting: 92
Ph III recruiting: 4
Growth YoY: +6.7%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 451–500 of 648 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02240719	Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer	completed	Phase 1	20	University of California, DavisOTHER	1	Jan 4, 2019	clinicaltrials
NCT01686321	Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma(B-R-ENDA)	completed	Phase 2	68	University of GöttingenOTHER	1	Dec 31, 2018